2-(4-(tert-Butoxycarbonyl)-1,4-diazepan-1-yl)-2-(thiophen-3-yl)acetic acid, 96%, 250mg

Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenyl-2-propen-1-yl]-, hydrochloride (1:2), 99%, 500g

3-Methyl-3-phenylbutanal, 95.0%, 250mg

4-methylidene-1-(propan-2-yl)bicyclo[3.1.0]hexane, 70%, 1g

2-Bromo-1-(3-fluoro-3-methyl-azetidin-1-yl)ethanone, 97%, 5g

TMS-HT (=HMDS and TMCS in Anhydrous Pyridine) [Trimethylsilylating Reagent, for OH compounds]12mL

(3-Chloro-4-fluorophenyl)(4-fluoro-4-((((5-methylpyrimidin-2-yl)methyl)amino)methyl)piperidin-1-yl)methanone, 98.0%, 50mg

(4-Amino-2-methyl-5-pyrimidinyl)methanol, 95.0%, 1g

3-(Trifluoromethyl)oxetan-3-ol, 98%, 1g

L(+)-allo-Threonine, 97.0%, 25g

Dimethyl 2-Aminoterephthalate, 97.0%, 25g

3-Fluorobenzonitrile, 98.0%, 25g

2,5-Dichloro-N-[2-(isopropylsulfonyl)phenyl]pyrimidin-4-amine>97.0%(HPLC)(N)1g